E-Book | May 18, 2023

Gene, Cell, & RNA Therapy Landscape: Q1 2023 Data Report

Source: Citeline
GettyImages-638075602 health data

In 2023, the first quarter witnessed a reduction in gene therapy products in Phase I and II clinical trials, continuing a trend from Q4 2022. One therapy, exagamglogene autotemcel, or exa-cel, for people with transfusion-dependent beta-thalassemia (TDT) or severe sickle cell disease (SCD), filed for approval in the first quarter.

Also in the gene therapy pipeline, oncology, and rare diseases remain the top areas of development overall and in the clinic. Those two areas remain the top areas of development in the pipeline of non-genetically modified cell therapies. In the RNA pipeline, rare diseases remain the top targeted therapeutic area, while anticancer therapies are the second most targeted area. In Q1 2023, companies signed 110 deals slightly fewer than the opening quarter of 2022 but similar to the previous two quarters. Series A and seed financings rebounded in Q1, reaching 17 transactions at $615.2 million. This represents nearly double the volume and value of Q4 2022.

Get insight from the 2023 first quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).

access the E-Book!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader